Johnson & Johnson Market Cap 2010-2023 | JNJ

Johnson & Johnson market cap history and chart from 2010 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Johnson & Johnson market cap as of April 12, 2024 is $355.49B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $355.491B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Novo Nordisk (NVO) Denmark $558.743B 46.03
Merck (MRK) United States $318.503B 83.83
AbbVie (ABBV) United States $287.341B 14.61
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53